Dimerization of the core domain of the p53 family: A computational study

Cell Cycle

Volumn 8, Issue 1, 2009, Pages 137-148

  Madhumalar, Arumugam ^a   Lee, Hui Jun ^a   Lane, David P ^b,c   Verma, Chandra Shekhar ^a  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c Agency for Science   (Singapore)

Author keywords

Cooperativity; MMGBSA; p53; p63; p73

Indexed keywords

PROTEIN P53; PROTEIN P63; PROTEIN P73; DNA; DNA BINDING PROTEIN; MUTANT PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ARTICLE; DIMERIZATION; DNA BINDING; DNA BINDING MOTIF; MATHEMATICAL ANALYSIS; OLIGOMERIZATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; AMINO ACID SEQUENCE; BIOLOGY; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; SURFACE PROPERTY; THERMODYNAMICS;

AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; DNA; DNA-BINDING PROTEINS; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SURFACE PROPERTIES; THERMODYNAMICS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 60749084685     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.1.7530     Document Type: Article

References (98)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
2. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, et al. Structural basis of DNA recognition by p53 tetramers. Mol Cell 2006; 22:741-53.
3. Das S, Boswell SA, Aaronson SA, Lee SW. p53 promoter selection: choosing between life and death. Cell Cycle 2008; 7:154-7.
4. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 2007; 6:1006-10.
5. Resnick MA, Tomso D, Inga A, Menendez D, Bell D. Functional diversity in the gene network controlled by the master regulator p53 in humans. Cell Cycle 2005; 4:1026-9.
6. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18:7621-36.
7. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4:793-805.
8. Clegg HV, Itahana K, Zhang Y. Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle 2008; 7:287-92.
9. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7.
10. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000; 19:1473-6.
11. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945-51.
12. Wawrzynow B, Zylicz A, Wallace M, Hupp T, Zylicz M. MDM2 chaperones the p53 tumor suppressor. J Biol Chem 2007; 282:32603-12.
13. Broude EV, Demidenko ZN, Vivo C, Swift ME, Davis BM, Blagosklonny MV, et al. p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle 2007; 6:1468-71.
14. Vives V, Slee EA, Lu X. ASPP2: a gene that controls life and death in vivo. Cell Cycle 2006; 5:2187-90.
15. Patel S, George R, Autore F, Fraternali F, Ladbury JE, Nikolova PV. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res 2008; 36:5139-51.
16. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8:781-94.
17. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer 2007; 96:196-200.
18. Robinson RA, Lu X, Jones EY, Siebold C. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63 and p73. Structure 2008; 16:259-68.
19. Finlan LE, Hupp TR. p63: the phantom of the tumor suppressor. Cell Cycle 2007; 6:1062-71.
20. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389:191-4.
21. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-19.
22. Soussi T, May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol 1996; 260:623-37.
23. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8.
24. Barbieri CE, Pietenpol JA. p63 and epithelial biology. Exp Cell Res 2006; 312:695-706.
25. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13.
26. Koster MI, Roop DR. p63 and epithelial appendage development. Differentiation 2004; 72:364-70.
27. van Bokhoven H, McKeon F. Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol Med 2002; 8:133-9.
28. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/ p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113:1661-70.
29. Hu W, Feng Z, Atwal GS, Levine AJ. p53: a new player in reproduction. Cell Cycle 2008; 7:848-52.
30. Oswald C, Stiewe T. In good times and bad: p73 in cancer. Cell Cycle 2008; 7:1726-31.
31. Villiard E, Brinkmann H, Moiseeva O, Mallette FA, Ferbeyre G, Roy S. Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer. BMC Evol Biol 2007; 7:180.
32. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing and dominant-negative activities. Mol Cell 1998; 2:305-16.
33. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
34. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 1996; 12:1379-85.
35. Tozluoglu M, Karaca E, Haliloglu T, Nussinov R. Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res 2008; 36:5033-49.
36. Bell HS, Ryan KM. Targeting the p53 family for cancer therapy: 'big brother' joins the fight. Cell Cycle 2007; 6:1995-2000.
37. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.
38. Kim E, Albrechtsen N, Deppert W. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene 1997; 15:857-69.
39. Mondal N, Parvin JD. The tumor suppressor protein p53 functions similarly to p63 and p73 in activating transcription in vitro. Cancer Biol Ther 2005; 4:414-8.
40. Ortt K, Sinha S. Derivation of the consensus DNA-binding sequence for p63 reveals unique requirements that are distinct from p53. FEBS Lett 2006; 580:4544-50.
41. Madhumalar A, Smith DJ, Verma C. Stability of the core domain of p53: insights from computer simulations. BMC Bioinformatics 2008; 9:17.
42. Canadillas JM, Tidow H, Freund SM, Rutherford TJ, Ang HC, Fersht AR. Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci USA 2006; 103:2109-14.
43. Halazonetis TD, Kandil AN. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. Embo J 1993; 12:5057-64.
44. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187:112-26.
45. McLure KG, Lee PW. How p53 binds DNA as a tetramer. Embo J 1998; 17:3342-50.
46. Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci USA 1993; 90:3319-23.
47. Patel S, Bui TT, Drake AF, Fraternali F, Nikolova PV. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding. Biochemistry 2008; 47:3235-44.
48. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265:346-55.
49. Ho WC, Fitzgerald MX, Marmorstein R. Structure of the p53 core domain dimer bound to DNA. J Biol Chem 2006; 281:20494-502.
50. Pan Y, Nussinov R. p53-Induced DNA bending: the interplay between p53-DNA and p53-p53 interactions. J Phys Chem B 2008; 112:6716-24.
51. Tu C, Tan YH, Shaw G, Zhou Z, Bai Y, Luo R, et al. Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. Acta Crystallogr D Biol Crystallogr 2008; 64:471-7.
52. Ma B, Levine AJ. Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements. Nucleic Acids Res 2007; 35:7733-47.
53. Lu Q, Tan YH, Luo R. Molecular dynamics simulations of p53 DNA-binding domain. J Phys Chem B 2007; 111:11538-45.
54. De Grandis V, Bizzarri AR, Cannistraro S. Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin. J Mol Recognit 2007; 20:215-26.
55. Pan Y, Nussinov R. Structural basis for p53 binding-induced DNA bending. J Biol Chem 2007; 282:691-9.
56. 2+ on DNA recognition and stability of the p53 DNA-binding domain. Biochemistry 2006; 45:7483-92.
57. Ma B, Pan Y, Gunasekaran K, Venkataraghavan RB, Levine AJ, Nussinov R. Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface. Proc Natl Acad Sci USA 2005; 102:3988-93.
58. Klein C, Georges G, Kunkele KP, Huber R, Engh RA, Hansen S. High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. J Biol Chem 2001; 276:37390-401.
59. Capturing cooperativity. Nat Chem Biol 2008; 4:433.
60. Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, Iwabuchi K, et al. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. Embo J 2002; 21:3863-72.
61. Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996; 274:1001-5.
62. Thukral SK, Blain GC, Chang KK, Fields S. Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1 and 53BP2. Mol Cell Biol 1994; 14:8315-21.
63. Tidow H, Veprintsev DB, Freund SM, Fersht AR. Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2). J Biol Chem 2006; 281:32526-33.
64. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19:607-14.
65. Chan WM, Siu WY, Lau A, Poon RY. How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 2004; 24:3536-51.
66. Rippin TM, Freund SM, Veprintsev DB, Fersht AR. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J Mol Biol 2002; 319:351-8.
67. Somani S, Chng CP, Verma CS. Hydration of a hydrophobic cavity and its functional role: a simulation study of human interleukin-1beta. Proteins 2007; 67:868-85.
68. Suresh A, Verma C. Modelling study of dimerization in mammalian defensins. BMC Bioinformatics 2006; 7:17.
69. Chène P, Jahnke W. Oligomerization of p53 upon Cooperative DNA Binding: Towards a Structural Understanding of p53 Function. Angew Chem Int Ed 2002; 41:1702-10.
70. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 downregulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21:1874-87.
71. Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, et al. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res 2008; 36:3639-54.
72. Dehner A, Klein C, Hansen S, Muller L, Buchner J, Schwaiger M, et al. Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. Angew Chem Int Ed Engl 2005; 44:5247-51.
73. Wang Y, Schwedes JF, Parks D, Mann K, Tegtmeyer P. Interaction of p53 with its consensus DNA-binding site. Mol Cell Biol 1995; 15:2157-65.
74. Cui Q, Karplus M. Allostery and cooperativity revisited. Protein Sci 2008; 17:1295-307.
75. Vijayakrishnan S, Qamra R, Verma CS, Sen R, Mande SC. Cation-mediated interplay of loops in chaperonin-10. J Biomol Struct Dyn 2006; 23:365-76.
76. Trylska J, McCammon JA, Brooks Iii CL. Exploring assembly energetics of the 30S ribosomal subunit using an implicit solvent approach. J Am Chem Soc 2005; 127:11125-33.
77. Habtemariam B, Anisimov VM, MacKerell AD Jr. Cooperative binding of DNA and CBFbeta to the Runt domain of the CBFalpha studied via MD simulations. Nucleic Acids Res 2005; 33:4212-22.
78. Bourdon JC. p53 Family isoforms. Curr Pharm Biotechnol 2007; 8:332-6.
79. Vashee S, Willie J, Kodadek T. Synergistic activation of transcription by physiologically unrelated transcription factors through cooperative DNA-binding. Biochem Biophys Res Commun 1998; 247:530-5.
80. Chong LT, Snow CD, Rhee YM, Pande VS. Dimerization of the p53 oligomerization domain: identification of a folding nucleus by molecular dynamics simulations. J Mol Biol 2005; 345:869-78.
81. Johnson RA, Shepard EM, Scotto KW. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J Biol Chem 2005; 280:13213-9.
82. Duneau JP, Vegh AP, Sturgis JN. A dimerization hierarchy in the transmembrane domains of the HER receptor family. Biochemistry 2007; 46:2010-9.
83. 1 checkpoint defect of monomeric p53 proteins. Oncogene 1996; 13:589-98.
84. Nicholls CD, McLure KG, Shields MA, Lee PW. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 2002; 277:12937-45.
85. Mateu MG, Sanchez Del Pino MM, Fersht AR. Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53. Nat Struct Biol 1999; 6:191-8.
86. Hanson S, Kim E, Deppert W. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. Oncogene 2005; 24:1641-7.
87. Romer L, Klein C, Dehner A, Kessler H, Buchner J. p53 - a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl 2006; 45:6440-60.
88. Weinberg RL, Veprintsev DB, Fersht AR. Cooperative binding of tetrameric p53 to DNA. J Mol Biol 2004; 341:1145-59.
89. Delphin C, Cahen P, Lawrence JJ, Baudier J. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur J Biochem 1994; 223:683-92.
90. Ishioka C, Shimodaira H, Englert C, Shimada A, Osada M, Jia LQ, et al. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. Biochem Biophys Res Commun 1997; 232:54-60.
91. Davison TS, Nie X, Ma W, Lin Y, Kay C, Benchimol S, et al. Structure and functionality of a designed p53 dimer. J Mol Biol 2001; 307:605-17.
92. Bower MJ, Cohen FE, Dunbrack RL Jr. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 1997; 267:1268-82.
93. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000; 33:889-97.
94. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, et al. The Amber biomolecular simulation programs. J Comput Chem 2005; 26:1668-88.
95. Wright JD, Noskov SY, Lim C. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain. Nucleic Acids Res 2002; 30:1563-74.
96. Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota FL, Eisenhaber F. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol 2007; 3:66.
97. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 2001; 98:10037-41.
98. DeLano WL. The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA, USA 2002.